1. The Association between the Body Mass Index, Chronic Obstructive Pulmonary Disease and SUV of the Non-Tumorous Lung in the Pretreatment [ 18 F]FDG-PET/CT of Patients with Lung Cancer.
- Author
-
Wehlte, Lukas, Walter, Julia, Daisenberger, Lea, Kuhnle, Felix, Ingenerf, Maria, Schmid-Tannwald, Christine, Brendel, Matthias, Kauffmann-Guerrero, Diego, Heinzerling, Lucie, Tufman, Amanda, Pfluger, Thomas, and Völter, Friederike
- Subjects
CHRONIC obstructive pulmonary disease ,BODY mass index ,LUNG cancer ,CANCER patients ,LUNGS - Abstract
Background: A debate persists on the prognostic value of the pre-therapeutic standardized uptake value (SUV) of non-tumorous lung tissue for the risk assessment of therapy-related pneumonitis, with most studies lacking significant correlation. However, the influence of patient comorbidities on the pre-therapeutic lung SUV has not yet been systematically evaluated. Thus, we aimed to elucidate the association between comorbidities, biological variables and lung SUVs in pre-therapeutic [
18 F]FDG-PET/CT. Methods: In this retrospective study, the pre-therapeutic SUV in [18 F]FDG-PET/CT was measured in non-tumorous areas of both lobes of the lung. SUVMEAN , SUVMAX and SUV95 were compared to a multitude of patient characteristics and comorbidities with Spearman's correlation analysis, followed by a Bonferroni correction and multilinear regression. Results: In total, 240 patients with lung cancer were analyzed. An elevated BMI was significantly associated with increased SUVMAX (β = 0.037, p < 0.001), SUVMEAN (β = 0.017, p < 0.001) and SUV95 (β = 0.028, p < 0.001). Patients with chronic obstructive pulmonary disease (COPD) showed a significantly decreased SUVMAX (β = −0.156, p = 0.001), SUVMEAN (β = −0.107, p < 0.001) and SUV95 (β = −0.134, p < 0.001). Multiple other comorbidities did not show a significant correlation with the SUV of the non-tumorous lung. Conclusions: Failure to consider the influence of BMI and COPD on the pre-therapeutic SUV measurements may lead to an erroneous interpretation of the pre-therapeutic SUV and subsequent treatment decisions in patients with lung cancer. [ABSTRACT FROM AUTHOR]- Published
- 2024
- Full Text
- View/download PDF